TERBILIV-250 is a very powerful antifungal tablet containing Terbinafine 250 mg. It is offered by Yodley Life Sciences through its Ulive Pharma unit. Terbinafine is an allylamine antifungal that has been clinically tested and approved for treating fungal nail and skin infections caused by dermatophytes. Unlike the azoles, which are fungistatic agents, Terbinafine is fungicidal and kills the fungi, thus making TERBILIV-250 very effective for dermatologists and other doctors.

TERBILIV-250 is produced in GMP-certified facilities, reflecting the dedication of Yodley Life Sciences to producing high-quality dermatological products for doctors, hospitals and pharmacies in India.

Composition

Terbinafine – 250 mg per tablet

Uses and Indications

TERBILIV-250 Tablets are prescribed by dermatologists, physicians, and general practitioners for the treatment of:

• Onychomycosis (fungal nail infection) of fingernails and toenails caused by dermatophytes
• Tinea pedis (athlete’s foot) — fungal infection of the feet
• Tinea cruris (jock itch) — fungal infection of the groin area
• Tinea corporis (ringworm) — fungal infection of the body
• Tinea capitis — scalp ringworm, particularly in children (as advised by a paediatrician)
• Cutaneous candidiasis — superficial skin infections caused by Candida species
• Other dermatomycoses resistant to topical antifungal therapy

How Terbinafine Tablets Work

Antifungal effects of Terbinafine result from its specific inhibition of squalene epoxidase enzyme, which is responsible for sterol biosynthesis in fungi. The inhibition of this enzyme causes the build-up of squalene and ergosterol deficiency, since ergosterol is the main sterol that constitutes the cell wall of the fungus. The squalene build-up causes direct toxicity to the fungus; therefore, Terbinafine is considered to be fungicidal, not fungistatic. Selectivity towards the fungal squalene epoxidase makes Terbinafine safe for humans.

Dosage and Administration

The tablets should only be taken orally and with or without food; they should be taken at the same time every day as prescribed by the physician. The duration of treatment will depend on the condition being treated; for example, if used for treating fungal nail infection, it may take several months to treat the disease since new nails take time to grow. Therefore, treatment should never be stopped prematurely.

Side Effects

TERBILIV-250 is generally well tolerated. Most commonly reported side effects are mild and transient, including:

• Nausea, indigestion, or mild abdominal discomfort
• Headache or mild dizziness
• Skin rash, itching, or urticaria
• Taste disturbance (dysgeusia) — loss or alteration of taste
• Abnormal liver enzyme elevations (monitored by periodic liver function tests)
• Rarely, serious hepatic adverse events have been reported; discontinue if jaundice occurs

Patients experiencing persistent or severe side effects should discontinue use and consult their physician promptly.

Precautions and Warnings

• To be used only under strict medical supervision; complete the whole course
• Advise your physician about any previous history of liver disease or hepatic impairment
• The patient’s liver function should be evaluated before starting treatment and periodically throughout long-term treatment
• In case of concomitant use of other medicines, inform your physician as some drugs might interfere with Terbinafine’s efficacy (e.g., warfarin, rifampicin, cyclosporine)
• Should be avoided during pregnancy and lactation
• Terbinafine is contraindicated for use in patients with immunodeficiency and renal impairment
• Not to be administered to children without medical consent and proper dosage adjustments

Contraindications

Terbinafine Tablets is contraindicated in patients with known hypersensitivity to Terbinafine or any excipient in the formulation. It should not be used in patients with chronic or active liver disease, and should be used with extreme caution in those with renal impairment.

Storage Instructions

Store Terbinafine Tablets below 25°C, in a dry place, protected from light and moisture. Keep in original blister packaging and out of reach of children and pets.

Packing Information

PCD Pharma Franchise for Terbinafine Tablets

Yodley Life Sciences invites pharma professionals, distributors, and medical representatives across India to partner for PCD Pharma Franchise and Monopoly Distribution rights of TERBILIV-250 and the complete Yodley antifungal and derma range. With WHO-GMP manufacturing and a 500+ product portfolio, Yodley Life Sciences is the preferred franchise partner in the antifungal segment.

Why Choose Yodley Life Sciences for PCD Pharma Franchise of Terbinafine Tablets?

• Monopoly-based PCD Pharma Franchise rights for TERBILIV-250 and the entire Yodley product range across district/state level
• Attractive profit margins and highly competitive pricing across all product categories
• WHO-GMP certified manufacturing ensuring consistent quality and 100% efficacy
• 500+ product portfolio covering tablets, capsules, syrups, injections, suspensions, dry syrups, and ayurvedic formulations
• Free promotional inputs – visual aids, MR bags, sample kits, reminder cards, and product literature
• Pan-India delivery with on-time order fulfilment and reliable supply chain
• Dedicated franchise support team for onboarding and ongoing business growth

Who Can Apply?

• Pharma professionals, distributors, and stockists looking to expand their antifungal/derma portfolio
• Medical representatives seeking to start their own independent PCD pharma business
• Existing pharma franchise partners wanting monopoly rights for TERBILIV-250 in their territory

For PCD Pharma Franchise enquiries for TERBILIV-250 and the complete Yodley Life Sciences product range, contact us today and become part of a fast-growing, quality-driven pharmaceutical network.

Disclaimer: TERBILIV-250 is a medicinal product. Use strictly under the supervision of a registered medical practitioner. This document is for informational and franchise marketing purposes only and does not constitute medical advice.